InVivo Therapeutics (NSDQ:NVIV) is continuing its momentum, saying today it added another clinical site, this time at the University of Louisville Hospital in Ky., to the Inspire trial testing its neuro-spinal scaffold.
The Cambridge, Mass.-based company’s neuro-spinal scaffold is surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
“I can appreciate the enormous unmet medical need presented by spinal cord injury, from both my experience as a practicing neurosurgeon and as a pharmacoeconomics researcher. I look forward to participating in this exciting study,” UofL site principal investigator Dr. Maxwell Boakye said in prepared remarks.
InVivo said the UofL location is both a clinical site and a data management center for the Cristopher and Dana Reeve Foundation’s North American Clinical Trials Network for the Treatment of Spinal Cord Injuries. The new site brings the total locations for the trial up to 17.
“We welcome UofL Hospital, our 1st NACTN site, to The Inspire Study. The hospital’s large catchment area and Dr. Boakye’s extensive expertise with leading spinal cord injury trials as part of NACTN will prove to be invaluable as we continue enrollment,” CEO Mark Perrin said in a press release.
Just yesterday, InVivo said it added a clinical site at the Vidant Medical Center in Greenville, N.C. to its Inspire study. A day earlier, InVivo said that the FDA accepted its proposed Humanitarian Device Exemption modular shell submission and review process for its Neuro-Spinal Scaffold.